临床药物基因组学实施联盟（CPIC）关于CYP2D6和CYP2C19基因分型与选择性5-羟色胺再摄取抑制剂给药的指南。
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
作者信息
Hicks J K, Bishop J R, Sangkuhl K, Müller D J, Ji Y, Leckband S G, Leeder J S, Graham R L, Chiulli D L, LLerena A, Skaar T C, Scott S A, Stingl J C, Klein T E, Caudle K E, Gaedigk A
机构信息
Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA.
出版信息
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
摘要
选择性5-羟色胺再摄取抑制剂（SSRIs）是治疗重度抑郁和焦虑症的主要药物。细胞色素P450 2D6（CYP2D6）和细胞色素P450 2C19（CYP2C19）基因多态性会影响SSRIs的代谢，进而影响药物疗效和安全性。我们总结了已发表文献中支持这些关联的证据，并根据CYP2D6和/或CYP2C19基因型给出了氟伏沙明、帕罗西汀、西酞普兰、艾司西酞普兰和舍曲林的给药建议（最新信息见www.pharmgkb.org）。
相似文献
1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.临床药物基因组学实施联盟（CPIC）关于CYP2D6和CYP2C19基因分型与选择性5-羟色胺再摄取抑制剂给药的指南。
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.
2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.临床药物遗传学实施联盟（CPIC）CYP2D6、CYP2C19、CYP2B6、SLC6A4 和 HTR2A 基因型及 5-羟色胺再摄取抑制剂类抗抑郁药指南
Clin Pharmacol Ther. 2023 Jul;114(1):51-68. doi: 10.1002/cpt.2903. Epub 2023 May 30.
3
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.荷兰药物遗传学工作组（DPWG）关于 CYP2C19 和 CYP2D6 与 SSRIs 之间基因-药物相互作用的指南。
Eur J Hum Genet. 2022 Oct;30(10):1114-1120. doi: 10.1038/s41431-021-01004-7. Epub 2021 Nov 16.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.临床药物遗传学实施联盟（CPIC）关于细胞色素 P450 2D6（CYP2D6）基因型背景下的可待因治疗指南。
Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28.
5
Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.CYP2C19和CYP2D6基因多态性对艾司西酞普兰血药浓度及其代谢率的联合影响：一项欧洲患者群体研究
Br J Clin Pharmacol. 2024 Oct;90(10):2630-2637. doi: 10.1111/bcp.16156. Epub 2024 Jun 26.
6
Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.细胞色素P450基因多态性对选择性5-羟色胺再摄取抑制剂作用及代谢的影响
Expert Opin Drug Metab Toxicol. 2015;11(8):1219-32. doi: 10.1517/17425255.2015.1052791. Epub 2015 Jun 1.
7
CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.CYP2C19 基因型可预测 GENDEP 中艾司西酞普兰的稳态浓度。
J Psychopharmacol. 2012 Mar;26(3):398-407. doi: 10.1177/0269881111414451. Epub 2011 Sep 17.
8
Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.多态性对健康志愿者舍曲林药代动力学、药效学和安全性的影响。
Basic Clin Pharmacol Toxicol. 2018 May;122(5):501-511. doi: 10.1111/bcpt.12938. Epub 2017 Dec 13.
9
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.CYP 代谢表型与选择性 5-羟色胺再摄取抑制剂引起的体重增加的相关性：一项回顾性队列研究。
BMC Med. 2022 Jul 26;20(1):261. doi: 10.1186/s12916-022-02433-x.
10
Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.遗传药理学因素对有双相情感障碍家族史的青少年人群中依地普仑药代动力学和不良反应的影响：一项初步研究。
J Child Adolesc Psychopharmacol. 2024 Feb;34(1):42-51. doi: 10.1089/cap.2023.0073.
引用本文的文献
1
Antidepressant drug switching in the Swiss population with a focus on Escitalopram and drugs with pharmacogenetic dosing guidelines: a drug utilization study using claims data.瑞士人群中抗抑郁药物的换药情况，重点关注艾司西酞普兰及有药物基因组学给药指南的药物：一项使用索赔数据的药物利用研究
Pharmacogenomics J. 2025 Aug 8;25(5):24. doi: 10.1038/s41397-025-00382-1.
2
Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.重度抑郁症抗抑郁治疗的药物遗传学意义：一项涵盖2019 - 2024年的系统综述
J Clin Med. 2025 Jul 18;14(14):5102. doi: 10.3390/jcm14145102.
3
Next-Generation Approaches in Sports Medicine: The Role of Genetics, Omics, and Digital Health in Optimizing Athlete Performance and Longevity-A Narrative Review.运动医学的下一代方法：遗传学、组学和数字健康在优化运动员表现和寿命方面的作用——一篇叙述性综述。
Life (Basel). 2025 Jun 27;15(7):1023. doi: 10.3390/life15071023.
4
Natural products proposed for the management of Huntington's disease (HD): a comprehensive review.用于治疗亨廷顿舞蹈症（HD）的天然产物：全面综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 17. doi: 10.1007/s00210-025-04444-w.
5
Research progress on the neural circuits mechanisms of anxiety.焦虑的神经回路机制研究进展
Front Neural Circuits. 2025 Jun 25;19:1609145. doi: 10.3389/fncir.2025.1609145. eCollection 2025.
6
The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment.药物递送系统对神经精神疾病治疗中药代动力学和药物相互作用的影响。
Cureus. 2025 Jun 8;17(6):e85563. doi: 10.7759/cureus.85563. eCollection 2025 Jun.
7
Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system.Geno4ME研究：在大型医疗保健系统中实施全基因组测序用于人群筛查。
NPJ Genom Med. 2025 Jul 1;10(1):50. doi: 10.1038/s41525-025-00508-1.
8
Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients.茄解定衍生的CYP2D6表型分析阐明了多药治疗老年患者中的表型转换。
Br J Clin Pharmacol. 2025 Jun;91(6):1842-1852. doi: 10.1111/bcp.70004.
9
Analysis of Gene Variant Frequencies in Iranian Population.伊朗人群基因变异频率分析
Iran J Med Sci. 2025 May 1;50(5):351-358. doi: 10.30476/ijms.2024.102645.3570. eCollection 2025 May.
10
An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression.氟伏沙明治疗抑郁症疗效的系统评价概述
Pharmaceuticals (Basel). 2025 May 12;18(5):711. doi: 10.3390/ph18050711.
本文引用的文献
1
Emergency department visits by adults for psychiatric medication adverse events.成人因精神科药物不良事件前往急诊科就诊的情况。
JAMA Psychiatry. 2014 Sep;71(9):1006-14. doi: 10.1001/jamapsychiatry.2014.436.
2
Pharmacogenetics of antipsychotics.抗精神病药物的药物遗传学。
Can J Psychiatry. 2014 Feb;59(2):76-88. doi: 10.1177/070674371405900203.
3
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.临床药物遗传学实施联盟 CYP2D6 基因型和可待因治疗指南：2014 年更新。
Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23.
4
A comparison of the risk of QT prolongation among SSRIs.SSRIs 类药物致 QT 延长风险的比较。
Ann Pharmacother. 2013 Oct;47(10):1330-41. doi: 10.1177/1060028013501994. Epub 2013 Oct 21.
5
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.细胞色素 P450 酶的遗传差异与抗抑郁治疗反应。
J Psychopharmacol. 2014 Feb;28(2):133-41. doi: 10.1177/0269881113512041. Epub 2013 Nov 20.
6
Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.迈向 CYP2D6 和 CYP2C19 基因型在临床实践中的实施：来自遗传药理学服务临床的更新和报告。
Int Rev Psychiatry. 2013 Oct;25(5):554-71. doi: 10.3109/09540261.2013.838944.
7
Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.细胞色素 P450 代谢和 5-羟色胺基因变异在精神药理学治疗中的临床有效性。
Int Rev Psychiatry. 2013 Oct;25(5):509-33. doi: 10.3109/09540261.2013.825579.
8
Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.基于群体药代动力学分析的中国人群中 CYP2D6*10 基因型对西酞普兰处置的估算。
J Clin Pharm Ther. 2013 Dec;38(6):504-11. doi: 10.1111/jcpt.12029. Epub 2013 Aug 28.
9
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南：2013 年更新。
Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
10
Pharmacogenomics knowledge for personalized medicine.药物基因组学知识与个性化医疗。
Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
Zotero 插件